ConcertAI Announces Predictive and Generative AI Platforms for Pharma Industry at ASCO 2024

Stock.adobe.com

ConcertAI announced predictive and generative AI solutions, along with a variety of other products, at the 2024 ASCO Annual Meeting. While all of the products are aimed at improving research and development capabilities within the life sciences industry, the AI offerings are reportedly the first-in-category offerings available to pharma researchers.

CARA AI is a digital platform that provides both predictive and generative AI services from research to clinical development. It is powered by real world data (RWD), and can reportedly take data entered from a variety of sources that have not been structured and present researchers with image/data curation, annotation, cohort generation, and analysis-ready data sets.

In a press release, ConcertAI’s CEO Jeff Elton, PhD, said, “Over the past two years, we have focused on the importance of multi-modal data AI model development, validation, stability monitoring, and deployment for insights, as part of clinical trials and, ultimately, clinical care. Multi-modal data enable causal inferences and elimination of confounders for interpretations and predictions. Enabling this required rethinking the tools available to biomedical researchers while leveraging the power of generative AI. As a new, ground-up approach that allows multi-modal data management, AI-model development validation, model management, and model release, we can bring the power of deep and wide data at scale, our large research network, and the latest predictive AI and gen AI together for the broadest research community use."

He continued, “ConcertAI's singular mission is to partner with leading medical societies, oncology research centers, and life science companies to create new approaches to high-depth, multi-modal data and clinical AI SaaS technologies to accelerate evidence generation and improve the accessibility of clinical trials, thereby improving treatment decisions across oncology care settings and assuring all eligible patients are rapidly and confidently identified."

Louis Culot is general manager of CancerLinQ, a network of cancer centers in the United States that is owned by ConcertAI. In the same press release, he discussed some of the ways that AI is being integrated into the network.

"The pace of progress in oncology is breathtaking," he said. "To keep up with this change–new drug approvals, new biomarkers, new research, new trial methods–and to be able to learn rapidly, requires novel approaches in AI, data, and informatics. At CancerLinQ, we are working with leading oncology centers at the forefront of this change."

ConcertAI also announced that it will be presenting a study at ASCO 2024 that shows the benefits of its Digital Trial Solutions platform.² The platform is powered by AI and reportedly streamlines the clinical trial site selection process. The study used models that simulated challenges that researchers might face during the selection process.

In a press release, Elton said, “This study confirms the utility of advanced AI and machine learning to optimize clinical trial designs and site selection. It further reflects the value of multi-AI model inferences, derived from multi-modal data, at national scale. By objectively analyzing massive datasets on investigator experience, patient populations, and site operations, the CARA ai supported analyses infer the most promising sites for sponsors more quickly and more accurately than traditional approaches. Streamlining this critical step gets new therapies into clinical trials quicker, which means getting life-saving treatments to patients sooner."

Sources

1. ConcertAI Introduces Predictive and Generative AI Solutions Powered by Multi-Modal Real-World Data, Key Partnerships, CARA AI, and More at the 2024 ASCO Annual Meeting. ConcertAI. May 31, 2024. https://www.prnewswire.com/news-releases/concertai-introduces-predictive-and-generative-ai-solutions-powered-by-multi-modal-real-world-data-key-partnerships-cara-ai-and-more-at-the-2024-asco-annual-meeting-302160078.html
2. ConcertAI: ASCO 2024 Study Indicates Multi-AI Model Scalability Key in Streamlining of Clinical Trial Site Selection Process. ConcertAI. May 30, 2024. Accessed May 31, 2024. https://www.prnewswire.com/news-releases/concertai-asco-2024-study-indicates-multi-ai-model-scalability-key-in-streamlining-of-clinical-trial-site-selection-process-302158870.html